Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the clinical benefit rate (CBR) after 24 weeks for ribociclib (LEE011) in combination with letrozole among postmenopausal women and men with hormone receptor positive, HER2- negative, advanced breast cancer who received no prior treatment for advanced disease. (70% group) To assess the clinical benefit rate (CBR) after 24 weeks for ribociclib (LEE011) in combination with letrozole and goserelin among pre-, and perimenopausal women who received no prior treatment for advanced disease as well as pre-, peri- and postmenopausal women and men with hormone receptor positive, HER2- negative, advanced breast cancer who received no more than 1 prior chemotherapy and 2 prior lines of endocrine therapy for advanced disease (30% group)
Critère d'inclusion
- HR+, HER2- advanced breast cancer